The Open Insulin Foundation (OIF) and Baltimore Under Ground Science Space (BUGSS) received a $137,000 grant from the Abell Foundation that leaders said will bring the organizations one step closer to a manufacturing phase of an affordably-priced therapeutic insulin.
In response to high prices that cause many with diabetes to ration insulin and suffer long-term health complications, the organizations partnered to develop a community-manufactured and affordable insulin alternative. It would enter a market where big pharmaceutical companies charge more than $250 for insulin.
“The motivation was to combat the way that pharmaceutical drugs are manufactured and marketed in the U.S. by developing an alternative and by returning that process back to the people who need it,” said Dr. Lisa Scheifele, executive director of BUGSS.
READ FULL ARTICLE HERE
